Experimental Flu Vaccines to Be Made at Duke

$7 million federal grant boosts Duke鈥檚 vaccine manufacturing initiative

A Duke Human Vaccine Institute researcher working in one of the new vaccine manufacturing labs
A Duke Human Vaccine Institute researcher working in one of the new vaccine manufacturing labs. Courtesy DHVI

The Duke Human Vaccine Institute has been awarded a $7 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), to manufacture H5N1 avian flu vaccines for use in clinical trials.

This particular strain of influenza has recently been identified in dairy cattle and is now present in herds in 18 states. The Centers for Disease Control and Prevention (CDC) has reported of avian flu in humans since April 2024.

鈥淲e will be developing two investigational mRNA vaccines targeting avian influenza, one is a more traditional vaccine, and one is a computationally-designed vaccine,鈥 said , chief operating officer of the  (DHVI). The mRNA approach is the same kind of vaccine used against COVID.

The award from NIAID, which is a part of the National Institutes of Health, is part of a contract called the Collaborative Influenza Vaccine Innovation Centers (), which NIAID set up to develop new influenza vaccines that induce long-lasting immunity and protect against more variants of the virus. DHVI is unusual in having a (cGMP) program that enables it to rapidly produce experimental new vaccines in sufficient quality and quantity to use in clinical trials.

The first investigational vaccine DHVI is being asked to make is more of a traditional design.

鈥淭he second mRNA vaccine that we鈥檙e making is what we call more of a central immunogen designed vaccine. Think of this as more of a central immunogen vaccine designed around the evolution of the virus,鈥 聽Denny said. 鈥淲ith this type of vaccine design the hope is that it will elicit a broad spectrum of antibodies against avian flu and reduce the need to adjust the vaccine periodically should we see new strains of avian flu develop.

鈥淭his is in contrast to what currently occurs for COVID vaccines as new strains develop and we need to frequently update the vaccine.鈥

If the virus that鈥檚 circulating now and has infected those 13 people changes a year from now, this vaccine could still provide coverage. The hope is also that a broadly effective vaccine would reduce or eliminate the need of boosting year after year as the type of flu changes.

DHVI employs a team science approach and collaborated with the research team at in the Netherlands who discovered the influenza immunogen.

鈥淲e expect to complete manufacturing this fall, with the goal of having vaccines ready for Phase 1 clinical trials to begin in early 2025,鈥 Denny said.